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Abstract
Myeloid leukemia of Down syndrome (ML-DS) is associated with good response to chemotherapy, resulting in favorable
outcomes. However, no universal prognostic factors have been identified to date. To clarify a subgroup with high risk of
relapse, the role of minimal residual disease (MRD) was explored in the AML-D11 trial by the Japanese Pediatric Leukemia/
Lymphoma Study Group. MRD was prospectively evaluated at after induction therapy and at the end of all chemotherapy,
using flow cytometry (FCM-MRD) and GATA1-targeted deep sequencing (GATA1-MRD). A total of 78 patients were
eligible and 76 patients were stratified to the standard risk (SR) group by morphology. In SR patients, FCM-MRD and
GATA1-MRD after induction were positive in 5/65 and 7/59 patients, respectively. Three-year event-free survival (EFS) and
overall survival (OS) rates were 93.3% and 95.0% in the FCM-MRD-negative population, and 60.0% and 80.0% in the
positive population. Three-year EFS and OS rates were both 96.2% in the GATA1-MRD-negative population, and 57.1% and
71.4% in the positive population. Adjusted hazard ratios for associations of FCM-MRD or GATA1-MRD with EFS were
10.98 (p= 0.01) and 27.68 (p < 0.01), respectively. Detection of MRD by either FCM or GATA1 after initial induction
therapy represents a significant prognostic factor for predicting ML-DS relapse.
Introduction
Myeloid leukemia of Down syndrome (ML-DS) shows
unique characteristics that translate into good treatment
response: predominance of acute megakaryoblastic leu-
kemia, age predilection during the first 4 years of life, and
higher sensitivity to chemotherapeutic agents. ML-DS
also displays increased treatment-related toxicities com-
pared to non-DS children with acute myeloid leukemia
(AML). As a result, ML-DS children have been treated
separately from non-DS AML children, with the appli-
cation of less intensive treatment in recent clinical studies
in developed countries resulting in long-term survival
rates of 80–90% [1–3].
On the other hand, relapsed and refractory cases of
ML-DS are rarely salvageable, even in patients receiving
hematopoietic stem cell transplantation [4]. Although pre-
vious studies have tried to identify prognostic factors pre-
dicting high-risk patients who might benefit from more
intensive chemotherapy in the frontline therapy, candidate
factors such as chromosomal abnormalities, age, and mor-
phological response have been poorly reproducible [3, 5, 6].
A previous study of children with de novo AML, however,
suggested that risk stratification based on minimal
residual disease (MRD) could improve outcomes [7]. The
AML-D11 study by the Japanese Pediatric Leukemia/
Lymphoma Study Group (JPLSG), a nationwide clinical
trial for ML-DS in Japan, was designed to evaluate the
feasibility and utility of MRD in the risk stratification of
patients with ML-DS, using flow cytometry (FCM) and
deep sequencing targeting GATA1 mutation.
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Between March 2012 and February 2015, patients with ML-
DS entered the AML-D11 study after informed consent was
obtained from the guardians. Eligibility criteria for this
study were as follows: (1) DS patients diagnosed with
myeloid leukemia irrespective of blast percentage; (2) age
>4 months and <18 years at diagnosis; (3) sufficient organ
function (patients with cardiac disease were eligible unless
serious complications were present); and (4) no history of
previous chemotherapy [except cytarabine treatment for
transient abnormal myelopoiesis (TAM)] or radiation ther-
apy. Patients with current TAM or CNS leukemia were not
eligible. The diagnosis was confirmed by a central mor-
phology review, with peripheral blood (PB) and bone
marrow (BM) smears reviewed by a pediatric hematologist,
and BM trephine biopsies in cases whose BM aspiration
was dry tap reviewed by a hematopathologist. Treatment
response was also evaluated by central review and was
defined as follows: M1 marrow, <5% blasts in the BM; M2
marrow, >5% and <25% blasts; M3 marrow, >25% blasts;
and complete remission (CR), M1 marrow with regenera-
tion of normal hematopoiesis and no leukemia-related
symptoms or extramedullary leukemic infiltration. This
study was approved by the JPLSG steering committee and
the institutional review boards of all institutions participat-
ing in this study. This trial was registered with the UMIN
Clinical Trials Registry (UMIN-CTR, URL: http://www.
umin.ac.jp/ctr/index.htm), number UMIN000007237.
Treatment
Treatment components in the AML-D11 study were iden-
tical to those in the prior AML-D05 study (Fig. 1 and Table
S1) [3]. All patients received a single course of induction
therapy comprising pirarubicin, intermediate-dose cytar-
abine (via 1-h intravenous infusion), and etoposide (CET),
then were stratified into two risk groups according to the
morphological BM response. Patients showing good
response (M1 marrow after initial CET) were classified as
standard risk (SR) and received less intensive chemother-
apy, in which etoposide was omitted from the 2nd and 4th
courses of CET. For patients displaying poor response (non-
M1 marrow after initial CET) classified as high risk (HR), a
salvage regimen with more intensive use of cytarabine was
given by either 24-h continuous infusion or a high dose. No
intrathecal chemotherapy was administered to either risk
group. The study protocol included supportive care guide-
lines such as empirical antimicrobial therapy, anti-fungal
prophylaxis, and monitoring and prophylactic supple-
mentation of intravenous immunoglobulin.
MRD study
MRD was measured by FCM (FCM-MRD) and deep
sequencing for GATA1 mutation (GATA1-MRD). Both
FCM- and GATA1-MRD were evaluated at two time points
for SR patients, after the induction therapy (time point 2;
TP-2) and at the end of all chemotherapy (time point S; TP-
S) (Fig. 1). For HR patients both FCM- and GATA1-MRD
were evaluated at four time points, after induction therapy
(TP-2), after re-induction therapies (Time points 3 and 4;
TP-3 and TP-4, respectively), and at the end of all che-
motherapy (Time point-H; TP-H).
FCM-MRD
FCM-MRD was performed at each time point in two
reference centers. Samples were shipped from the referring
institutions and processed within 24–48 h of collection
using methods similar to those used in the previous report
[7]. Briefly, mononuclear cells from diagnostic samples (PB
samples were also allowed if BM was unavailable) were
separated by centrifugation on a density step (Histopaque-
1077, Sigma-Aldrich, St. Louis, MO). We incubated
mononuclear cells with rabbit serum for 2 min to block Fc
receptors and washed them in phosphate buffered saline
containing 0.2% bovine serum albumin and 0.2% sodium
azide (PBSA) and labeled with combinations of
fluorochrome-conjugated monoclonal antibodies directed
against surface antigens, or isotype-matched nonreactive
Fig. 1 Treatment outline of the AML-D11 study. Abbreviations:
BMA: bone marrow aspiration, CET: Pirarubicin, etoposide, cytar-
abine (100 mg/m2, 1 hr i.v.), CR: complete remission, CT: Pirarubicin,
cytarabine (100 mg/m2, 1 hr i.v.), cCVT: Pirarubicin, vincristine,
cytarabine (100 mg/m2, 24 hr continuous i.v.), hCE: etopiside, high-
dose cytarabine (1 g/m2, 2 hr i.v x2/day), MRD: minimal residual
disease.
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monoclonal antibodies. The marker antibody combinations
used to study FCM-MRD were as follows: (1) anti-CD38
fluorescein isothiocyanate (FITC; Beckman Coulter), anti-
CD11b phycoerythrin (PE; BD Biosciences), anti-CD34
peridinin chlorophyll protein (PerCP; BD Biosciences),
anti-CD117 allophycocyanin (APC; Miltenyi Biotec), anti-
CD33 phycoerythrin-Cy7 (PE-Cy7;BD Biosciences), anti-
CD45 APC-H7 (BD Biosciences), anti-CD7 Brilliant
Violet421 (BV421; BD Biosciences), and anti-HLA-DR
BV510 (BD Biosciences); (2) anti-CD41 FITC (DAKO),
anti-CD56 PE (BD Biosciences), anti-CD34 PerCP, anti-
CD117 APC, anti-CD33 PE-Cy7p, anti-CD45 APC-H7,
anti-CD7 BV421, and anti-CD4 Violet 500 (V500; Biole-
gend). After incubation for 10 min at 20 °C in the dark,
we washed the cells in PBSA twice, fixed them in 0.5%
paraformaldehyde, and analyzed using a three-lasers-
FACSCantoII or FACSVerse flow cytometer with FACS-
Diva™ software (Becton Dickinson, San Jose, CA). Side by
side comparisons of the results obtained in diagnostic AML
samples and in reference control samples were performed to
define leukemia-associated immunophenotypes.
To monitor FCM-MRD according to leukemia-
associated immunophenotypes, marker combinations that
allowed identification of MRD for each patient were
selected. We acquired data from all mononuclear cells in
each test tube (>1 × 105).
To determine the proportion of mononuclear cells within
each sample and to distinguish them from residual ery-
throcytes, platelet aggregates and debris, cells in one tube
were stained with SYTO-13 (50 nmol/L; Molecular Probes,
Eugene, OR). FCM-MRD-positivity pre-specified as
≥0.05% and leukemic cell clustering was reviewed by two
operators.
In statistical analyses, patients for whom MRD positivity
was not evaluable were excluded from the calculation of
proportions. Results of MRD analysis were blinded to
investigators and patients.
GATA1-MRD
GATA1 mutations were analyzed by Sanger sequencing
using diagnostic samples, as previously described [3, 8–10].
Targeted deep sequencing for GATA1 was retrospectively
performed using pooled BM or PB samples at diagnosis and
GATA1-MRD was monitored using BM samples at each
time point, as previously described [3]. Briefly, genomic
DNA was extracted from BM and/or PB using the QIAamp
DNA Blood Mini Kit (QIAGEN, Venlo, the Netherlands).
Polymerase chain reaction (PCR) was performed for
exons 2 and 3 of GATA1 using primers that flanked each
of the exons. Primers used for PCR were 135 sense
(5ʹ-AGGTAGAAGCAGATGAGAGTGGA-3ʹ) and AS3
(5ʹ-GTGGGGTGGAGAGGAGAAGAGGGA-3ʹ). Forty ng
of genomic DNA was used as a template for PCR. PCR was
performed in a total volume of 50 μL consisting of 5 μL of
10x PCR buffer for KOD-Plus-Neo, 0.2 mM of dNTPs,
1.5 mM of MgSO4, 0.5 μM of each primer, and 1 μL of
KOD-Plus-Neo (TOYOBO, Osaka, Japan). We performed
PCR in a three-step cycle. Initial denaturation at 94 °C for
2 min, followed by 26 cycles of denaturation at 98 °C
for 10 s, annealing at 67 °C for 30 s, and extension at 68 °C
for 60 s. PCR products were purified using QIAquick PCR
purification kit (QIAGEN). Each amplicon was subsequently
used for sequencing library preparation using the Nextera
XT library kit (Illumina, San Diego, CA). Sequencing was
done on a MiSeq sequencer with 150 bp pair end reads. Each
library was indexed with a barcode and reads were auto-
matically partitioned post sequencing. After quality trim-
ming, reads from each sample were aligned to the human
genome reference sequence (GRCh37/hg19), and the CLC
Genomic Workbench 7.5 (CLC Bio, Aarhus, Denmark) was
used for mapping and variant calling with the low frequency
variant detection methods. To eliminate sequencing errors,
we excluded all variants found in a control sample (HEL
cells). The cutoff for mutation-positive status was set as
0.3% for mutation detection at diagnosis. Patient-specific
target mutations detected at allele frequencies ≥0.1% for
males or ≥0.05% for females in follow-up samples were
considered GATA1-MRD-positive, with this difference due
to the fact that GATA1 gene is located on the X chromo-
some. Cases with complex mutations were removed from
the analysis because low frequency mutations may not be
detected.
Definitions and statistics
The primary endpoint was MRD positivity after induction
and intensification therapy (TP-2, -3, -4, -S, and -H).
Secondary endpoints were evaluability of MRD, reasons
for an unevaluable sample (e.g., dry tap), the proportion
of patients with GATA1 mutation, event-free survival
(EFS) rate, overall survival (OS) rate, and adverse events
during induction and intensification therapy. EFS was
defined as the length of time from registration to failure to
achieve remission, relapse, secondary malignancy, or
death from any cause, whichever came first. OS was
defined as the length of time from registration to death
from any cause. Time-to-event for patients who did not
experience the event in question was censored as of the
date of last follow-up.
Sample size of the study was derived by prespecifying
the width of the 95% confidence interval (CI) of estimated
proportions of MRD-positive patients. We specified
that the width of the 95% CI was narrower than 0.2.
The required sample size was 62 patients for a true pro-
portion of 20%. Assuming a 5–10% rate of ineligible
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patients, the target number of registered patients was
set at 75.
MRD after induction and intensification therapy and
adverse events were described using proportions and 95%
CI. EFS and OS rates were described using the
Kaplan–Meier method. Prognostic factors for EFS and OS
of AML-DS were explored using Cox regression analysis.
Potential prognostic factors identified in the prior AML-
D05 (age, sex, mosaic 21 trisomy, history of TAM, car-
diac complications, FAB classification, white blood cell
count, hemoglobin level, platelet count, abnormal cyto-
genetics, and GATA1 mutation) were initially screened
using univariate log-rank tests. Only factors identified as
significant from univariate analyses were included in
multivariate Cox regression analysis. Proportional hazards
assumptions were confirmed from log-negative log
graphs.
All reported p-values were two-sided, and we considered
values of p < 0.05 as statistically significant. An academic
statistician conducted all analyses using SAS version
9.4 software (SAS Institute, Cary, NC). The date of data
cutoff was as of July 13, 2018.
Results
Patient characteristics
A total of 82 patients were registered to this study. Four
patients were judged ineligible due to severe comorbidities
(n= 3), and initiation of chemotherapy prior to registration
(n= 1). As a result, 78 patients were eligible for analysis
(Fig. 2). The relevant initial clinical and hematological data
of the 78 patients in this study are shown in Table 1.
Median age at diagnosis was 16 months (range,
4–48 months). Ten patients had mosaic trisomy 21 and 43
patients (58%) had a history of TAM. Seventy-three percent
of patients (n= 47) showed cardiac disease at presentation.
Forty-five patients (58%) had BM blast exceeding 20%,
whereas 33 (42%) had <20% of BM blasts. Karyotype
analysis showed monosomy 7 in 15 patients, complex
karyotype (defined as presence of a clone with at least three
unrelated cytogenetic abnormalities) in 8 patients, and 20
patients with normal karyotype and sole constitutional
trisomy 21. GATA1 mutations were identified in 76 of 78
patients (97%).
Treatment outcome
After induction therapy, 76 of 78 patients (97.4%) achieved
CR and were stratified to the SR group, whereas one patient
did not achieve CR and received intensive chemotherapy
according to the HR regimen. Another patient died of car-
diac failure during initial CET. No therapy-related deaths
were observed during intensification therapy.
During the follow-up period (median, 4.0 years; range,
0.7–5.7 years), seven patients showed relapse in BM within
5–20 months after registration; all seven patients were in the
SR group. One patient in the HR group could not achieve CR
after intensive salvage therapy and died of disease progres-
sion. No extramedullary relapse including CNS was observed.
The 3-year EFS and OS rates in the entire population (n= 78)
were 87.2% (95% CI, 77.5–92.9%) and 89.7% (95% CI,
80.5–94.7%). The 3-year EFS and OS rates in the SR patients
Fig. 2 Flow diagram of
patients in the AML-D11
study. FCM flow cytometry,
MRD minimal residual disease.
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(n= 76) were 89.5% (95% CI, 80.1–94.6%) and 92.1% (95%
CI, 83.3–96.4%), respectively (Fig. 3).
Toxic events
As grade 4 adverse events, sepsis was observed in two
patients (2 events) during initial induction therapy and
elevation of liver enzyme was observed in one patient
(1 event) during the intensification phases. One toxic death
due to cardiac failure was observed during remission, but no
other severe cardiac sequelae were observed during follow-
up. Secondary cancer was also not reported. The therapy-
related mortality rate in this study was thus 1.3%.
FCM-MRD
Longitudinal profiles of FCM-MRD at TP-2, -3, -4, and at TP-
S, -H are shown in Table S2. Of the 76 patients in the SR
group, 65 patients (85.5%) were evaluable for FCM-MRD at
TP-2. Eleven patients (14.5%) could not be evaluated because
of dry tap (n= 1), no sample submission (n= 3), and failure of
setting MRD targets (n= 7). The 3-year EFS and OS rates in
the analysis population for FCM-MRD (n= 65) were 90.8%
(95% CI, 80.6–95.7%) and 93.8% (95% CI, 84.4–97.6%),
respectively. Five patients (7.5%) were positive (range,
0.088–1.441%), and all five samples had the cluster of blasts.
Two of these five patients showed relapse in BM, at 7 and
20 months after completion of chemotherapy. Of 60 patients
whose end-of-induction FCM-MRD was negative, three
patients relapsed. At TP-S, one of the 55 patients with evalu-
able samples was positive. FCM-MRD in this patient was also
positive after initial induction therapy and the patient was alive
without relapse as of final follow-up. As expected, one patient
in the HR group was MRD-positive (30.2%) at TP-2.
GATA1-MRD
In the SR group, 59 patients (77.6%) were evaluable for
GATA1-MRD at TP-2, whereas 17 patients could not be
evaluated because of no sample submission (n= 1) or
failure of setting MRD targets (n= 16) (Table S3). Of the
seven positive patients (11.9%), three patients relapsed and
two subsequently died. In contrast, 2 of 52 patients with
negative GATA1-MRD suffered relapse. At TP-S, 53 sam-
ples (70.1%) were evaluable and one patient was positive;
this patient survived without relapse. The mean coverage of
sequencing in each sample ranged 59,922x to 281,121x
with a median of 170,693x (Figure S1).
Concordance between FCM-MRD and GATA1-MRD
Correlations between MRD results are depicted in Figure
S2. Among the 54 SR patients for whom both FCM-MRD
Table 1 Baseline characteristics of patients in total and standard
risk populations for which FCM-MRD was assessable at time
point 2.
Total (n= 78) Standard risk
population with
FCM-MRD (n= 65)
N % N %





4–23 60 76.9 50 76.9
24 or older 18 23.1 15 23.1
Girl 37 47.4 32 49.2
21 trisomy mosaic
Yes 10 13.2 6 9.5
No 66 86.8 57 90.5
Not available 2 2
History of TAM
Yes 43 58.1 36 58.1
No 31 41.9 26 41.9
Not available 4 3
Cardiac complication
Yes 47 73.4 39 75.0
No 17 26.6 13 25.0
BM blast percentage
30% or more 27 34.6 18 27.7
20–29% 18 23.1 16 24.6
5–19% 31 39.7 29 44.6
>5% 2 2.6 2 3.1














49 (5–250) 43 (5–191)
Cytogenetics
Normal karyotype* 20 26.0 17 26.2%
Monosomy 7 7 9.1 6 9.2%
Monosomy 7
(complex)
8 10.4 7 10.8%
Sole trisomy 8 2 2.6 1 1.5%
Complex 8 10.4 7 10.8%
1q loss 7 9.1 5 7.7%
7p loss 10 13.0 10 15.4%
Acquired +21 10 13.0 7 10.8%
Other 32 41.6 27 41.5%
Not available 1 0
GATA1 mutation
Negative 2 2.6 1 1.5%
Positive 76 97.4 64 98.5%
MRD minimal residual disease, TAM transient abnormal myelopoiesis
*Normal karyotype means 47, XX,+ 21c or 47, XY,+ 21c.
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and GATA1-MRD were analyzed, 50 patients (92.6%)
showed concordant classification based on FCM-MRD
and GATA1-MRD (either both positive or both
negative). All four patients showing discordant results
survived without relapse. Among the seven relapses
in SR patients, five patients each were evaluable by
FCM-MRD and GATA1-MRD, respectively. Two
patients were positive in both FCM-MRD and GATA1-
MRD, one was positive only in GATA1-MRD, and
four were negative or missing in both FCM-MRD and
GATA1-MRD.
Prognostic factors
Table 2 and S4 show results of uni- and multivariate Cox
regression analysis for prognostic factors among SR
patients. FCM-MRD and GATA1-MRD after initial induc-
tion therapy (TP-2) represented significant prognostic fac-
tors for predicting relapse in SR patients. Three-year EFS
and OS rates were 93.3% (95% CI, 83.2–97.4%) and 95.0%
(95% CI, 85.3–98.4%) in the FCM-MRD-negative popu-
lation, compared to 60.0% (95% CI, 12.6–88.2%) and
80.0% (95% CI, 20.4–96.9%) in the FCM-MRD-positive
Fig. 3 Survival curve of the patients with standard risk (n= 76). (a) Event-free survival and (b) overall survival for patients showing good
response after initial induction therapy.
Table 2 Multivariate Cox
regression of FCM-MRD or
GATA1-MRD for event-free and
overall survivals in the standard
risk population.
EFS OS
HR 95%CI p HR 95%CI p
Analysis of FCM-MRD (n= 65, including 5 MRD-positive patients)
MRD at Time point 2
Negative Ref Ref
Positive 10.98 1.70–70.89 0.01 5.74 0.52–63.50 0.15
Cytogenetics
Other abnormalities Ref Ref
1q loss 4.61 0.45–47.54 0.20 6.31 0.54–73.74 0.14
Platelet (per 1010/L increase) 1.17 0.98–1.39 0.09 1.13 0.90–1.41 0.31
Analysis of GATA1-MRD (n= 59, including 7 MRD-positive patients)
MRD at Time point 2
Negative Ref Ref
Positive 27.68 2.84–269.89 <0.01 15.08 1.37–166.56 0.03
Cytogenetics
Other abnormalities Ref Ref
1q loss 11.55 0.68–197.24 0.09 10.19 0.62–168.08 0.10
Platelet (per 1010/L increase) 1.14 0.93–1.41 0.20 1.09 0.85–1.38 0.50
MRD minimal residual disease, EFS event-free survival, OS overall survival HR hazard ratio CI confidence
interval
T. Taga et al.
population, respectively (Fig. 4a, b). Three-year EFS and
OS rates were both 96.2% (95% CI, 85.5–99.0%) in the
GATA1-MRD-negative population, while 57.1% (95% CI,
17.2–83.7%) and 71.4% (95% CI, 25.8–92.0%) in the
GATA1-MRD-positive population, respectively (Figs. 4c,
d). Hazard ratios for the associations of FCM-MRD and
GATA1-MRD with EFS were 10.98 (95% CI, 1.70–70.89;
p= 0.01) and 27.68 (95% CI, 2.84–269.89; p < 0.01),
respectively, after adjusting for other prognostic factors
(Table 2).
Irrespective of methodologies, MRD at the end of
chemotherapy (TP-S) did not have any prognostic impact.
Age at diagnosis <2 years that was significantly associated
with favorable prognosis in the previous study [3], did not
show any impact in the present study. Furthermore, sig-
nificant prognostic factors in univariate analyses such as
chromosomal abnormalities (1q loss) and platelet count
were not associated with unfavorable EFS or OS rates in
multivariate analysis.
Discussion
In this study of 78 patients with ML-DS, FCM identified
5 MRD-positive patients among 65 patients who
achieved CR, while GATA1-targeted deep sequencing
detected 7 MRD-positive patients among 59 patients with
CR. These patients with MRD positivity after achieving
morphological CR were at significantly high risk of
relapse, revealing EFS rates around 60%. Although a
small subset of patients whose end-of-induction MRD
was negative eventually relapsed (four patients
with FCM-MRD and two patients with GATA1-MRD),
hazard ratios for the associations of FCM-MRD and
Fig. 4 Event-free survival and overall survival of patients with
standard risk according to FCM-MRD (n= 65) or GATA1-MRD
(n= 59). (a) event-free survival according to FCM-MRD, (b) overall
survival according to FCM-MRD, (c) event-free survival according to
GATA1-MRD, (d) overall survival according to GATA1-MRD.
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GATA1-MRD with EFS were striking (10.98 and 27.68,
respectively).
To establish a therapeutic approach for ML-DS with
reduced dose intensity than that applied for non-DS AML
patients, identification of prognostic factors is essential for
appropriate risk stratification. Several factors have been
identified as prognostic in past ML-DS studies worldwide,
but no universal prognostic factors have been established to
date. The prognostic impact of FCM-MRD after initial
induction therapy has been shown in several studies for
pediatric de novo AML [7, 11] and also in the COG
AAML0431 study for ML-DS [2]. In this AML-D11 study,
the prognostic impact of MRD was shown not only by
FCM, but also by deep sequencing for GATA1. Although
GATA1-MRD was analyzed retrospectively, the results of
outcome and FCM-MRD were masked at the time of
GATA1-MRD analysis. GATA1 mutation is well known as
the hallmark of ML-DS blasts, but no previous reports have
examined MRD using GATA1 mutation in ML-DS patients.
A high rate (98%) of detecting GATA1 mutation from
screening both BM and PB samples at initial diagnosis
could contribute to showing the impact and effectiveness of
GATA1-MRD in this study [10]. Taken together, MRD after
initial induction therapy could offer a universal prognostic
factor for ML-DS. Because obstacles to the introduction of
GATA1-MRD into clinical use remain, due to costs and a
labor-intensive procedure, applying FCM-MRD for the risk
stratification of treatment for ML-DS appears reasonable.
Therefore, it is necessary to refine the marker combination
panels to improve the sensitivity and specificity of
FCM-MRD.
Less intensive chemotherapy compared with Western
countries has been used in Japanese studies for ML-DS
without compromising treatment outcomes [12]. Moreover,
further dose reduction was successfully shown in the
JPLSG AML-D05 study [3], the backbone of which we
applied in the AML-D11 study. Combined with the results
from the Toronto group study with an ultra-low-dose
cytarabine-based regimen that contained no anthracyclines
and no etoposide [13], further dose reductions might be
possible for specific subgroups. As many patients with ML-
DS show comorbidities, pursuit of possibilities for appro-
priate dose reduction among patients expected to show good
prognosis has been one of the strategies for the Japanese
pediatric AML committee. On the other hand, our retro-
spective study of patients ineligible for enrollment in
clinical trials showed that an excessively reduced intensity
of chemotherapy might not be curative [14]. To address this
issue, dose modification according to the end-of-induction
FCM-MRD is attempted in the ongoing Japan Children’s
Cancer Group AML-D16 study (jrct.niph.go.jp,
jRCTs041190047). Although the number of patients who
will be influenced by refined risk stratification based on the
MRD analyses might be small, treatment intensification in
end-of-induction MRD-positive patients and reduction in
treatment burden in patients whose MRD clearance is
excellent may contribute to further improvement in not only
treatment outcome but also quality of life of DS patients
with AML. As an HR patient who did not achieve CR in
this study eventually succumbed to the disease, establishing
treatment strategies for refractory/relapsed patients is also
imperative.
Acknowledgements The authors deeply appreciate the invaluable
cooperation of the large number of physicians working at the institu-
tions, central diagnostic laboratories, and the office and data center of
the JPLSG. We also wish to thank Dario Campana and Elaine
Coustan-Smith (National University of Singapore) for helpful discus-
sions regarding FCM-MRD analysis. This work was supported by a
Grant for Clinical Cancer Research and a Grant-in-Aid for Cancer
Research from the Ministry of Health, Labour, and Welfare of Japan.
This work was supported in part by the Project Promoting Clinical
Trials for Development of New Drugs (JP19lk0201061t0004) and
Practical Research for Innovative Cancer Control (JP19ck0106329)
from the Japan Agency for Medical Research and Development
(AMED) and by Grants-in-Aid for scientific research from the Min-
istry of Education, Culture, Sports, Science, and Technology of Japan
(KAKENHI: 26253061, 18H04039).
Author contributions T.Tag (principal investigator), Daisuke H, TM,
YH, HM, HN, HT, AS, and DT participated actively in the study con-
ception and design; Ta.Ta., ST, Daisuke H, and DT reviewed the data
analysis and interpretation and were the main authors of the paper; AMS
and ST conducted the statistical analyses; SI and HH were responsible
for immunodiagnostics and FCM-MRD analysis; KT, EI, and T.Tok
were responsible for GATA1 mutation and GATA1-MRD analysis; T.Tak
was responsible for coordinating the molecular biological analyses; AH
was responsible for diagnosis and treatment response by morphology;
MI was responsible for diagnosis by pathology; KK, Daiichiro H, and
AH recruited patients; and Ta.Ta., ST, and SA contributed financial and
administrative support for the study. All authors contributed to the
conduct of the trial and were involved in the review of the results and the
final approval of the paper.
Compliance with ethical standards
Conflict of interest The authors declare no competing interest.
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
References
1. Uffmann M, Rasche M, Zimmermann M, von Neuhoff C,
Creutzig U, Dworzak M, et al. Therapy reduction in patients with
Down syndrome and myeloid leukemia: the international ML-DS
2006 trial. Blood .2017;129:3314–21.
2. Taub JW, Berman JN, Hitzler JK, Sorrell AD, Lacayo NJ, Mast K,
et al. Improved outcomes for myeloid leukemia of Down syn-
drome: a report from the Children’s Oncology Group AAML0431
trial. Blood .2017;129:3304–13.
3. Taga T, Watanabe T, Tomizawa D, Kudo K, Terui K, Moritake H,
et al. Preserved high probability of overall survival with sig-
nificant reduction of chemotherapy for myeloid leukemia in Down
T. Taga et al.
syndrome: a nationwide prospective study in Japan. Pediatr Blood
Cancer. 2016;63:248–54.
4. Taga T, Saito AM, Kudo K, Tomizawa D, Terui K, Moritake H,
et al. Clinic al characteristics and outcome of refractory/relapsed
myeloid leukemia in children with Down syndrome. Blood.
2012;120:1810–5.
5. Gamis AS, Woods WG, Alonzo TA, Buxton A, Lange B, Barnard
DR, et al. Increased age at diagnosis has a significantly negative
effect on outcome in children with Down syndrome and acute
myeloid leukemia: a report from the Children’s Cancer Group
Study 2891. J Clin Oncol. 2003;21:3415–22.
6. Blink M, Zimmermann M, von Neuhoff C, Reinhardt D, de Haas
V, Hasle H, et al. Normal karyotype is a poor prognostic factor in
myeloid leukemia of Down syndrome: a retrospective, interna-
tional study. Haematologica. 2014;99:299–307.
7. Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J,
et al. Minimal residual disease-directed therapy for childhood
acute myeloid leukaemia: results of the AML02 multicentre trial.
Lancet Oncol. 2010;11:543–52.
8. Xu G, Nagano M, Kanezaki R, Toki T, Hayashi Y, Taketani T, et al.
Frequent mutations in the GATA-1 gene in the transient myelo-
proliferative disorder of Down syndrome. Blood .2003;102:2960–8.
9. Kanezaki R, Toki T, Terui K, Xu G, Wang R, Shimada A, et al.
Down syndrome and GATA1 mutations in transient abnormal
myeloproliferative disorder: mutation classes correlate with pro-
gression to myeloid leukemia. Blood. 2010;116:4631–8.
10. Terui K, Toki T, Taga T, Iwamoto S, Miyamura T, Hasegawa D,
et al. Highly sensitive detection of GATA1 mutations in patients
with myeloid leukemia associated with Down syndrome by
combining Sanger and targeted next generation sequencing. Genes
Chromosomes Cancer. 2020;59:160–7.
11. Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC,
Hirsch BA, et al. Residual disease detected by multidimensional
flowcytometry signifies high relapse risk in patients with de novo
acute myeloid leukemia:a report from Children’s Oncology
Group. Blood 2012;120:1581–8.
12. Kudo K, Kojima S, Tabuchi K, Yabe H, Tawa A, Imaizumi M,
et al. Prospective study of a pirarubicin, intermediate-dose
cytarabine, and etoposide regimen in children with Down
syndrome and acute myeloid leukemia: the Japanese
Childhood AML Cooperative Study Group. J Clin Oncol.
2007;25:5442–7.
13. Al-Ahmari A, Shah N, Sung L, Zipursky A, Hitzler J. Long-term
results of an ultra low-dose cytarabine-based regimen for the
treatment of acute megakaryoblastic leukaemia in children with
Down syndrome. Br J Haematol. 2006;133:646–8.
14. Nakashima K, Hasegawa D, Tomizawa D, Miyamura T, Hama A,
Iwamoto S, et al. Characteristics and outcomes of children
with acute myeloid leukemia and Down syndrome who are
ineligible for clinical trials due to severe comorbidities.
Pediatr Blood Cancer. 2019;66:e27942 https://doi.org/10.1002/
pbc.27942
Affiliations
Takashi Taga 1 ● Shiro Tanaka2 ● Daisuke Hasegawa 3 ● Kiminori Terui4 ● Tsutomu Toki 4 ● Shotaro Iwamoto 5 ●
Hidefumi Hiramatsu 6 ● Takako Miyamura 7 ● Yoshiko Hashii8 ● Hiroshi Moritake 9 ● Hideki Nakayama 10 ●
Hiroyuki Takahashi 11 ● Akira Shimada12 ● Tomohiko Taki13 ● Etsuro Ito 4 ● Asahito Hama 14 ● Masafumi Ito15 ●
Katsuyoshi Koh 16 ● Daiichiro Hasegawa17 ● Akiko M. Saito18 ● Souichi Adachi19 ● Daisuke Tomizawa 20
1 Department of Pediatrics, Shiga University of Medical Science,
Otsu, Japan
2 Department of Clinical Biostatistics, Graduate School of Medicine
Kyoto University, Kyoto, Japan
3 Department of Pediatrics, St Luke’s International Hospital,
Tokyo, Japan
4 Department of Pediatrics, Hirosaki University Graduate School of
Medicine, Hirosaki, Japan
5 Department of Pediatrics, Mie University Graduate School of
Medicine, Tsu, Japan
6 Department of Pediatrics, Graduate School of Medicine Kyoto
University, Kyoto, Japan
7 Department of Pediatrics, Osaka University Graduate School of
Medicine, Suita, Japan
8 Department of Cancer Immunotherapy, Osaka University
Graduate School of Medicine, Suita, Japan
9 Division of Pediatrics, Department of Reproductive and
Developmental Medicine, Faculty of Medicine, University of
Miyazaki, Miyazaki, Japan
10 Department of Pediatrics, Kyushu Cancer Center, Fukuoka, Japan
11 Department of Pediatrics, Toho University, Tokyo, Japan
12 Department of Pediatrics, Okayama University Graduate School of
Medicine, Okayama, Japan
13 Laboratory of Clinical Hematology, Department of Medical
Technology, Kyorin University Faculty of Health Sciences,
Mitaka, Japan
14 Department of Hematology and Oncology, Children’s Medical
Center, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan
15 Department of Pathology, Japanese Red Cross Nagoya First
Hospital, Nagoya, Japan
16 Department of Hematology/Oncology, Saitama Children’s
Medical Center, Saitama, Japan
17 Department of Hematology/Oncology, Hyogo Children’s Medical
Center, Kobe, Japan
18 Clinical Research Center, National Hospital Organization Nagoya
Medical Center, Nagoya, Japan
19 Human Health Science, Kyoto University, Kyoto, Japan
20 Division of Leukemia and Lymphoma, Children’s Cancer Center,
National Center for Child Health and Development, Tokyo, Japan
Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of. . .
